Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Upgraded by Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

A number of other equities research analysts have also recently commented on the stock. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research report on Wednesday. Stifel Nicolaus increased their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $54.73 on Friday. Supernus Pharmaceuticals has a 1-year low of $29.16 and a 1-year high of $59.68. The business has a fifty day moving average price of $50.69 and a 200 day moving average price of $48.30. The stock has a market capitalization of $3.14 billion, a P/E ratio of -80.48, a price-to-earnings-growth ratio of 1.73 and a beta of 0.71.

Insider Activity

In related news, Director Bethany Sensenig sold 4,475 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 710 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the sale, the vice president owned 14,508 shares in the company, valued at approximately $644,735.52. This trade represents a 4.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,185 shares of company stock valued at $1,268,022 in the last three months. 8.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of SUPN. Hantz Financial Services Inc. increased its stake in shares of Supernus Pharmaceuticals by 81.7% during the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares during the period. Torren Management LLC purchased a new position in Supernus Pharmaceuticals in the fourth quarter worth $49,000. USA Financial Formulas purchased a new position in Supernus Pharmaceuticals in the 3rd quarter valued at approximately $50,000. Smartleaf Asset Management LLC raised its position in shares of Supernus Pharmaceuticals by 30.8% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 268 shares during the last quarter. Finally, Global Retirement Partners LLC raised its position in shares of Supernus Pharmaceuticals by 532.4% in the fourth quarter. Global Retirement Partners LLC now owns 1,404 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 1,182 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.